8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  June  11, 2007

                              MYMETICS CORPORATION
             (Exact name of registrant as specified in its charter)

         Delaware                      000-25132                 25-1741849
(State of other jurisdiction          (Commission               (IRS Employer
     of incorporation)                File Number)           Identification No.)

               14, rue de la Colombiere
                1260 Nyon, Switzerland                            NA
       (Address of principal executive offices)               (Zip Code)

Registrant's telephone number, including area code: +011 41 22 363 13 10


         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))









ITEM 3.02  UNREGISTERED SALES OF EQUITY SECURITIES.

         The Registrant ("Mymetics") issued a total of 14,862,000 restricted
shares of its common stock to an investor in connection with his equity
investment of E800,000 (equal to approximately $1,078,516) for 5,393,000 shares
of Mymetics common stock at a per share price of $0.20 compared to the market
bid price of approximately $0.10 on the date of the sale of those shares and
9,469,000 shares of its common stock in connection with the conversion of loans
in the principal amount of E930,000 plus accrued and unpaid interest. The board
of directors of Mymetics also approved the issuance of 6,000,000 shares of its
common stock to Christian Rochet, President of Mymetics, and 5,000,000 shares of
its common stock to each of Ernst Luebke, CFO of Mymetics, and Dr. Sylvain
Fleury, CSO of Mymetics, in recognition of their contributions to Mymetics that
were critical to receiving the equity investment referenced above and other
advances by Mymetics toward achievement of its business plan. All the above
shares were issued in reliance upon the exemption from registration provided by
Section 4(2) of the Securities Act based upon, among other things, the size and
manner of the offering.

ITEM 8.01 OTHER EVENTS.

         Mymetics issued a press release dated June 5, 2007 describing recent
positive results for its HIV vaccine in developing mucosal antibodies to combat
the AIDS virus in non-human primates. A copy of the press release is attached
hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

     (c) Exhibits

         99.1 Press Release



                                      -1-




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date: June 18, 2007                     MYMETICS CORPORATION



                                        By: /s/ Ernst Luebke
                                            -------------------------------
                                            Ernst Luebke
                                            Chief Financial Officer






                                      -2-

EX-99.1

                                                                Exhibit 99.1


           MYMETICS' HIV VACCINE DEMONSTRATES FIRST-EVER PRODUCTION OF
         MUCOSAL NEUTRALIZING IGA ANTIBODIES IN NON-HUMAN PRIMATE MODEL

    NYON, Switzerland, June 07 /PRNewswire-FirstCall/ -- Mymetics Corporation
(Nasdaq: MYMX.PK) announced today analysis of results demonstrating that the
Company's HIV vaccine elicited neutralizing IgA mucosal antibodies in a
non-human primate model. Mucosal IgA antibodies are considered as a possible
first line of defense against infection by HIV. The data were presented by
Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer, in an oral
presentation titled, "Without Mucosal Adjuvant, Virosomes-gp41 Peptides from the
MPR can Elicit Protective Mucosal IgA in Vaccinated Macaques," at the recent
Keystone Symposium, HIV Vaccines: From Basic Research to Clinical Trials.

    According to the findings, more than 90 percent of non-human primates
vaccinated with virosomes expressing the HIV-1 gp41 peptide produced mucosal IgA
antibodies in the genital and intestinal compartments. These mucosal antibodies
were capable of preventing HIV transcytosis, a process by which HIV crosses the
membrane epithelium of the mucosa, by 60 to 98 percent. When total IgA was
purified for testing in standard neutralizing assays (TZMbl), the IgA antibodies
also showed the ability to neutralize a primary HIV clade B virus (QH0692) known
to be difficult to neutralize. Mucosal IgA produced against the HIV gp41 protein
after vaccination was determined to be as good or better than the best anti-HIV
neutralizing monoclonal antibodies (2F5, 4E10 and b12) currently on the market,
when comparing the amount of antibodies required for neutralizing 50 percent of
the viruses.

    Mymetics' Dr. Fleury commented, "These results are extremely encouraging. We
believe that, by using virosomes which target the mucosal compartment, we now
have a means to elicit neutralizing IgA that can potentially work at low
concentrations. Furthermore, virosomes do not require a mucosal adjuvant for
triggering mucosal antibodies. This may cut the time to market since mucosal
adjuvants are not currently marketed for human use."

    Dr. Fleury added, "Mymetics and its collaborators are the first group to
report neutralizing IgA obtained after vaccination against HIV in non-human
primate. In the coming year, Mymetics intends to conduct another study in
non-human primates for testing of an improved vaccine version. Pending positive
results, we may be able to file to initiate a clinical trial and begin phase I
testing some time in late 2008."

    Mymetics Vaccine Program Background

    Worldwide, over 85 percent of HIV infections are the result of sexual
transmission in which mucosal tissues from the genital and anorectal regions
have been exposed to HIV-1 present in semen or secretions. According to a recent
report from the International AIDS Vaccine Initiative, "Since an effective
preventive AIDS vaccine will primarily have to protect an individual from sexual
transmission of HIV, researchers think it will probably be important for a
vaccine candidate to induce strong mucosal immune responses."



Mymetics-affiliated researchers have been able to engineer gp41-derived antigens
(proteins and peptides) capable of eliciting antibodies, particularly IgA
antibodies, with strong potential for preventing in vitro virus translocation
across the mucosal barrier and/or to inhibit cell infection, thus preventing
HIV-1 infection.

    Mymetics has combined three important concepts in its vaccine design:

      1- Induction of mucosal and blood antibodies to allow protection in
      different anatomical compartments and block the early event of HIV
      translocation at the genito-reproductive and intestine tracts and
      subsequent infection of target cells underlying the mucosal tissues,
      thereby preventing HIV entry and spreading in the body.

      2- Focusing the immune response against conserved regions on gp41 that may
      induce protective antibodies against a broad range of HIV clades. Mymetics
      is developing vaccines that contain antigens expressing limited
      immunodominant regions, while immunodistractive regions have been removed
      or altered without affecting the immunogenicity of the antigen.

      3- Minimal mimicry. This aspect is important when dealing with HIV
      proteins that have several known homologies with human proteins.
      Developing antibodies against such native HIV proteins may lead to
      cross-reactions toward human proteins and, consequently, increased risk of
      developing potential long-term autoimmunity side-effects after vaccination
      with unmodified HIV proteins. Mymetics' concept is to use a small
      engineered HIV protein sequence (gp41) that has been mostly deleted of its
      human protein homologies. This innovative concept is expected to render
      the vaccine effective against HIV while providing a safer alternative to
      other vaccine approaches.

    About Mymetics

    Mymetics was founded in 1990 near Lyon, France and was registered as a US
(Delaware) public company in 2000. Since August 2003, its operations and
research programs have been managed out of Switzerland (Nyon, near Geneva).

    Mymetics Common shares trade on NASDAQ's OTC:PK under the symbol MYMX. For
more information, please visit the Company's website at
http://www.mymetics.com/.




    Forward-Looking Statements

    The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements, which are identified by the words
"believe," "expect," "anticipate," "intend," "plan" and similar expressions. The
statements contained herein which are not based on historical facts are
forward-looking statements that involve known and unknown risks and
uncertainties that could significantly affect our actual results, performance or
achievements in the future and, accordingly, such actual results, performance or
achievements may materially differ from those expressed or implied in any
forward-looking statements made by or on our behalf. These risks and
uncertainties include, but are not limited to, risks associated with our ability
to successfully develop and protect our intellectual property, our ability to
raise additional capital to fund future operations and compliance with
applicable laws and changes in such laws and the administration of such laws.
See Mymetics' Form 10-K for the fiscal years ended December 31, 2005 and
December 31, 2006 for a discussion of such risks, uncertainties and other
factors. Readers are cautioned not to place undue reliance on these forward-
looking statements which speak only as of the date the statements were made.